Skip to main content

Table 1 Baseline characteristics compared between HFpEF and controls

From: Impact of different degrees of left ventricular strain on left atrial mechanics in heart failure with preserved ejection fraction

Characteristics

HFpEF (n = 79)

Controls (n = 158)

p-value

Age (years)

71.6 ± 11.5

70.6 ± 10.0

0.491

Male gender

29 (36.7%)

58 (36.7%)

1.000

Body mass index (kg/m2)

26.8 ± 5.6

26.6 ± 4.6

0.767

NYHA-II

68 (86.1%)

NYHA-III

11 (13.9%)

Hyperlipidemia

51 (64.6%)

116 (73.4%)

0.159

Diabetes

44 (55.7%)

85 (53.8%)

0.782

Hypertension

61 (77.2%)

114 (72.2%)

0.403

History of myocardial infarction

5 (6.3%)

0 (0.0%)

0.164

History of revascularization

7 (8.9%)

0 (0%)

0.333

History of atrial fibrillation

19 (24.1%)

2 (1.3%)

 < 0.001

Mitral regurgitation

28 (35.4%)

21 (13.3%)

 < 0.001

Medication use

   

 Aspirin

28 (43.1%)

63 (47.4%)

0.569

 Statin

43 (66.2%)

95 (71.4%)

0.448

 β-blockers

38 (58.5%)

77 (57.9%)

0.939

 ACEi

9 (13.8%)

16 (12.0%)

0.718

 ARB

18 (27.7%)

42 (31.6%)

0.576

 Diuretics

27 (41.5%)

31 (23.3%)

0.008

  1. Data presented as mean ± standard deviation or number and percentage
  2. ACEi angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; HFpEF heart failure with preserved ejection fraction; NYHA New York Heart Association functional class
  3. A p-value < 0.05 indicates statistical significance (bold and italic)
  4. Medication data were available for 83.5% (n = 198) of total subjects